Cullinan Therapeutics (CGEM) Gains from Investment Securities: 2020-2024
Historic Gains from Investment Securities for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to $10.4 million.
- Cullinan Therapeutics' Gains from Investment Securities fell 275.15% to -$9.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $786,000, marking a year-over-year decrease of 97.92%. This contributed to the annual value of $10.4 million for FY2024, which is 334.60% up from last year.
- Latest data reveals that Cullinan Therapeutics reported Gains from Investment Securities of $10.4 million as of FY2024, which was up 334.60% from -$4.4 million recorded in FY2023.
- Over the past 5 years, Cullinan Therapeutics' Gains from Investment Securities peaked at $10.4 million during FY2024, and registered a low of -$4.4 million during FY2023.
- For the 3-year period, Cullinan Therapeutics' Gains from Investment Securities averaged around $5.1 million, with its median value being $9.3 million (2022).
- As far as peak fluctuations go, Cullinan Therapeutics' Gains from Investment Securities plummeted by 147.49% in 2023, and later spiked by 334.60% in 2024.
- Yearly analysis of 5 years shows Cullinan Therapeutics' Gains from Investment Securities stood at $4.6 million in 2020, then soared by 100.58% to $9.3 million in 2021, then rose by 0.81% to $9.3 million in 2022, then crashed by 147.49% to -$4.4 million in 2023, then skyrocketed by 334.60% to $10.4 million in 2024.